pralatrexate + cyclophosphamide + vincristine + prednisone

This is a **combination chemotherapy regimen** consisting of pralatrexate, cyclophosphamide, vincristine, and prednisone, designed for the treatment of peripheral T-cell lymphomas (PTCL), including subtypes such as PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma. The regimen alternates courses of cyclophosphamide, etoposide, vincristine, and prednisone (CEOP) with pralatrexate. **Pralatrexate** is an antifolate agent that inhibits dihydrofolate reductase, blocking DNA synthesis and promoting cancer cell death. **Cyclophosphamide** is an alkylating agent interfering with DNA replication, **vincristine** is a vinca alkaloid that inhibits microtubule formation to prevent cell division, and **prednisone** is a glucocorticoid with lympholytic and anti-inflammatory properties. This combination aims to increase response rates and allow more patients to proceed to stem cell transplantation, although studies have not shown superiority to conventional regimens for front-line treatment of PTCL[1][2][3][4].

Brand names

Folotyn + COP

Other names

Fol-COP